cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Edgewise Therapeutics Inc
2 own
3 watching
Current Price
$16.37
$-0.12
(-0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
651.1M
52-Week High
52-Week High
20.69000
52-Week Low
52-Week Low
5.12000
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization651.1M
icon52-Week High20.69000
icon52-Week Low5.12000
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio--
What does the Edgewise Therapeutics Inc do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company s lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Read More
How much money does Edgewise Therapeutics Inc make?
News & Events about Edgewise Therapeutics Inc.
Business Wire
1 year ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its...
Business Wire
1 year ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41st Annual...
Business Wire
1 year ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today plans to host a virtual investor call on Tuesday, January 3, 2023...
Business Wire
1 year ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development...
Business Wire
1 year ago
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following...
Frequently Asked Questions
Frequently Asked Questions
What is Edgewise Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Edgewise Therapeutics Inc shares?
plus_minus_icon
How can I buy Edgewise Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Edgewise Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Edgewise Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Edgewise Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Edgewise Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Edgewise Therapeutics Inc?
plus_minus_icon
What percentage is Edgewise Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Edgewise Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$16.37
$-0.12
(-0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00